Published in Semin Dial on October 02, 2002
In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide. Kidney Int (2009) 2.09
Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res (2014) 2.02
HDL metabolism and activity in chronic kidney disease. Nat Rev Nephrol (2010) 1.32
Management of cardiovascular disease in patients with kidney disease. Nat Rev Cardiol (2013) 1.23
IL-1β receptor antagonist reduces inflammation in hemodialysis patients. J Am Soc Nephrol (2011) 1.21
Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease. Clin J Am Soc Nephrol (2011) 1.20
Examining associations of circulating endotoxin with nutritional status, inflammation, and mortality in hemodialysis patients. J Ren Nutr (2011) 1.11
Inflammation and its impact on anaemia in chronic kidney disease: from haemoglobin variability to hyporesponsiveness. NDT Plus (2009) 1.09
Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease. Osteoporos Int (2009) 1.08
Haemodiafiltration-optimal efficiency and safety. NDT Plus (2009) 1.05
Plasma S100A12 level is associated with cardiovascular disease in hemodialysis patients. Clin J Am Soc Nephrol (2011) 1.00
Associations of interleukin-6, C-reactive protein and serum amyloid A with mortality in haemodialysis patients. Nephrology (Carlton) (2008) 0.99
N-acetyl-seryl-aspartyl-lysyl-proline attenuates renal injury and dysfunction in hypertensive rats with reduced renal mass: council for high blood pressure research. Hypertension (2009) 0.98
Effects of sevelamer and calcium-based phosphate binders on lipid and inflammatory markers in hemodialysis patients. Am J Nephrol (2007) 0.98
Cardiovascular risk and management in chronic kidney disease. Nat Rev Nephrol (2009) 0.96
Association of interleukin (IL)-4 intron-3 and IL-6 -174 G/C gene polymorphism with susceptibility to end-stage renal disease. Immunogenetics (2007) 0.95
HDL proteome in hemodialysis patients: a quantitative nanoflow liquid chromatography-tandem mass spectrometry approach. PLoS One (2012) 0.95
Causes of dysregulation of lipid metabolism in chronic renal failure. Semin Dial (2009) 0.94
Low levels of vitamin C in dialysis patients is associated with decreased prealbumin and increased C-reactive protein. BMC Nephrol (2011) 0.93
Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis. Immunobiology (2012) 0.93
Hypoalbuminaemia--a marker of cardiovascular disease in patients with chronic kidney disease stages II-IV. Int J Med Sci (2008) 0.91
Chronic Inflammation and Coronary Atherosclerosis in Patients with End-Stage Renal Disease. Cardiorenal Med (2012) 0.91
Therapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filters. Immunobiology (2014) 0.91
Coronary artery calcification in chronic kidney disease: An update. World J Cardiol (2014) 0.88
Chronic kidney disease delays VLDL-apoB-100 particle catabolism: potential role of apolipoprotein C-III. J Lipid Res (2009) 0.87
Salutary effects of hemodialysis on low-density lipoprotein proinflammatory and high-density lipoprotein anti-inflammatory properties in patient with end-stage renal disease. J Natl Med Assoc (2011) 0.84
Inflammatory marker but not adipokine predicts mortality among long-term hemodialysis patients. Mediators Inflamm (2007) 0.84
Repositioning Clofazimine as a Macrophage-Targeting Photoacoustic Contrast Agent. Sci Rep (2016) 0.84
Effect of exercise on cardiac tissue oxidative and inflammatory mediators in chronic kidney disease. Am J Nephrol (2008) 0.83
Post-transcriptional nature of uremia-induced downregulation of hepatic apolipoprotein A-I production. Transl Res (2012) 0.83
High mobility group box protein-1 correlates with microinflammatory state and nutritional status in continuous ambulatory peritoneal dialysis patients. J Artif Organs (2011) 0.82
Reasons for the lack of salutary effects of cholesterol-lowering interventions in end-stage renal disease populations. Blood Purif (2013) 0.82
Statins in the management of dyslipidemia associated with chronic kidney disease. Nat Rev Nephrol (2012) 0.82
Serum Concentrations of F2-Isoprostanes and 4-Hydroxynonenal in Hemodialysis Patients in Relation to Inflammation and Renal Anemia. Biomark Insights (2008) 0.82
Restless legs syndrome in dialysis patients: a comparison between hemodialysis and continuous ambulatory peritoneal dialysis. Neurol Sci (2012) 0.80
Advanced glycation end-products, a pathophysiological pathway in the cardiorenal syndrome. Heart Fail Rev (2012) 0.80
Understanding the role of genetic polymorphisms in chronic kidney disease. Pediatr Nephrol (2008) 0.80
Endotoxin binding by sevelamer: potential impact on nutritional status. Int J Nephrol (2013) 0.78
Hemodialysis and water quality. Semin Dial (2013) 0.78
Optimizing haemodialysate composition. Clin Kidney J (2015) 0.78
Vascular calcification: When should we interfere in chronic kidney disease patients and how? World J Nephrol (2016) 0.78
Cross-over study of influence of oral vitamin C supplementation on inflammatory status in maintenance hemodialysis patients. BMC Nephrol (2013) 0.78
Adiponectin receptor and adiponectin signaling in human tissue among patients with end-stage renal disease. Nephrol Dial Transplant (2014) 0.78
Is inflammation a new risk factor of depression in haemodialysis patients? Int Urol Nephrol (2012) 0.77
Factors precipitating erythropoiesis-stimulating agent responsiveness in a European haemodialysis cohort: case-crossover study. Pharmacoepidemiol Drug Saf (2015) 0.76
Relationship between inflammatory cytokines and cardiorenal anemia syndrome: treatment with recombinant human erythropoietin (rhepo). Hippokratia (2008) 0.75
Effect of inflammation on nutritional status of patients on maintenance hemodialysis. Indian J Nephrol (2016) 0.75
The systemic nature of CKD. Nat Rev Nephrol (2017) 0.75
Diagnosis and Management of Cardiovascular Disease in Advanced and End-Stage Renal Disease. J Am Heart Assoc (2016) 0.75
Stop chronic kidney disease progression: Time is approaching. World J Nephrol (2016) 0.75
Statins for renal patients: a fiddler on the roof? Int J Nephrol (2012) 0.75
Transcriptome analysis in patients with chronic kidney disease on hemodialysis disclosing a key role for CD16+CX3CR1+ monocytes. PLoS One (2015) 0.75
Is Fibroblast growth factor 23 the leading cause of increased mortality among chronic kidney disease patients? A narrative review. J Adv Res (2017) 0.75
The Strategy to Prevent and Regress the Vascular Calcification in Dialysis Patients. Biomed Res Int (2017) 0.75
The platelet-to-lymphocyte ratio as an inflammation marker in non-dipper hypertensive patients. Hippokratia (2016) 0.75
Heart failure with preserved ejection fraction: a nephrologist-directed primer. Heart Fail Rev (2017) 0.75
Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. Clin J Am Soc Nephrol (2007) 2.19
Comparison of nutritional and inflammatory markers in dialysis patients with reduced appetite. Am J Clin Nutr (2007) 2.07
Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. J Am Soc Nephrol (2002) 2.03
Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: implications for patient survival. Am J Kidney Dis (2009) 1.28
Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease. Clin J Am Soc Nephrol (2008) 1.22
Left ventricular function in patients with chronic kidney disease evaluated by colour tissue Doppler velocity imaging. Nephrol Dial Transplant (2005) 1.09
Improvement of cardiac function after haemodialysis. Quantitative evaluation by colour tissue velocity imaging. Nephrol Dial Transplant (2004) 0.99
Effect of bicarbonate on muscle protein in patients receiving hemodialysis. Am J Kidney Dis (2006) 0.97
Inflammation contributes to low plasma amino acid concentrations in patients with chronic kidney disease. Am J Clin Nutr (2005) 0.96
Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. Am J Kidney Dis (2007) 0.96
Changes in fat mass correlate with changes in soluble sCD163, a marker of mature macrophages, in patients with CKD. Am J Kidney Dis (2006) 0.90
Statin treatment and diabetes affect myeloperoxidase activity in maintenance hemodialysis patients. Clin J Am Soc Nephrol (2006) 0.85
Postprandial metabolic response to a fat- and carbohydrate-rich meal in patients with chronic kidney disease. Nephrol Dial Transplant (2010) 0.83
Acute effects of low and high intravenous doses of furosemide on myocardial function in anuric haemodialysis patients: a tissue Doppler study. Nephrol Dial Transplant (2007) 0.82
Overestimation of advanced oxidation protein products in uremic plasma due to presence of triglycerides and other endogenous factors. Clin Chim Acta (2007) 0.81
Inflammation modifies the association of osteoprotegerin with mortality in chronic kidney disease. J Nephrol (2009) 0.80
Plasma reduced homocysteine and other aminothiol concentrations in patients with CKD. Am J Kidney Dis (2006) 0.79
Combined hypertriglyceridemic and insulin-glucose clamps for the characterization of substrate oxidation and plasma elimination of a long-chain triglyceride emulsion in healthy men. Metabolism (2011) 0.78
Pentraxin 3, a sensitive early marker of hemodialysis-induced inflammation. Blood Purif (2012) 0.78
Hyperhomocysteinemia in relation to plasma free amino acids, biomarkers of inflammation and mortality in patients with chronic kidney disease starting dialysis therapy. Am J Kidney Dis (2004) 0.76
Environmental lead exposure and chronic renal disease. N Engl J Med (2003) 0.76
Proteome patterns in uremic plasma. Blood Purif (2008) 0.75